4//SEC Filing
Davis Robert E 4
Accession 0001209191-18-002591
CIK 0001567514other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:09 PM ET
Size
14.0 KB
Accession
0001209191-18-002591
Insider Transaction Report
Form 4
Davis Robert E
SVP, Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2018-01-03+65,164→ 65,164 totalExercise: $15.47Exp: 2028-01-03→ Common Stock (65,164 underlying) - Award
Restricted Stock Units
2018-01-03+48,480→ 48,480 total→ Common Stock (48,480 underlying) - Exercise/Conversion
Common Stock
2018-01-03+2,648→ 30,512 total - Sale
Common Stock
2018-01-04$15.60/sh−1,115$17,394→ 29,397 total - Exercise/Conversion
Restricted Stock Units
2018-01-03−2,648→ 5,298 total→ Common Stock (2,648 underlying)
Footnotes (6)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- [F3]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F4]On January 3, 2017, the reporting person was granted 7,946 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F5]On January 3, 2018, the reporting person was granted options to purchase 65,164 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F6]On January 3, 2018, the reporting person was granted 48,480 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Documents
Issuer
Intra-Cellular Therapies, Inc.
CIK 0001567514
Entity typeother
Related Parties
1- filerCIK 0001291959
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 8:09 PM ET
- Size
- 14.0 KB